BCL2L1 and central nervous system cancer: Streffer and his colleagues showed that BCL-2 family protein expression (Bcl-xL and BAX) could modulate radiosensitivity in human glioma cells and targeted alterations in BCL-2 family protein expression might be a promising strategy to improve the therapeutic efficacy of radiotherapy for gliomas [30].